Abstract
Objectives: Assessment of the diagnostic value of serum CEA, CA 15.3, osteocalcin (OC) and β-CrossLaps (β-CTX) in the detection of metastatic breast cancer. Design and methods: This study included 47 patients with breast cancer (20 non-metastatic breast cancer, 11 bone metastasis, 11 soft tissue metastasis, 5 bone plus soft tissue metastasis), 10 patients with benign breast lesions and 13 healthy volunteers. CEA and CA 15.3 were determined using microparticle enzyme immunoassay; while OC and β-CTX were measured by electrochemiluminescence immunoassay. Results: CEA, CA 15.3, OC and β-CTX median levels were higher in breast cancer patients compared to controls ( p = 0.006, 0.001, 0.004 and 0.038, respectively). Increased levels of OC and β-CTX were demonstrated in bone metastatic patients compared to non-metastatic or soft tissue metastatic patients ( p = 0.000). Conclusions: Combined use of OC and β-CTX could be useful in early detection of bone metastatic breast cancer which might improve the outcome of the disease.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
